Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Century Therapeutics, Inc.IPSC · Entity 5739 | Chief Finanical Officer | March 11, 2025 | March 12, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Century Therapeutics, Inc.
Report date March 11, 2025 · Filed March 12, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 79,648 |
Reported balance
After 2025-03-11 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2025-03-11 · Grant · Acquired 19,500 · Balance 79,648 F1: Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Issuer common stock. The RSUs vest 25% on March 11, 2026, with the remaining 75% vesting on a quarterly basis for the three years thereafter, in each case subject the Reporting Person's continued service through the applicable vesting date. The RSUs will be settled on each applicable vesting date in shares of the Issuer's common stock. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.60 · Expires 2035-03-11 | Direct | 19,500 |
Reported balance
After 2025-03-11 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-03-11 · Grant · Acquired 19,500 · Balance 19,500 F2: The option vests 25% on March 11, 2026, with the remaining 75% vesting in 36 equal monthly installments, subject to the Reporting Person's continued service through each applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Issuer common stock. The RSUs vest 25% on March 11, 2026, with the remaining 75% vesting on a quarterly basis for the three years thereafter, in each case subject the Reporting Person's continued service through the applicable vesting date. The RSUs will be settled on each applicable vesting date in shares of the Issuer's common stock.
F2: The option vests 25% on March 11, 2026, with the remaining 75% vesting in 36 equal monthly installments, subject to the Reporting Person's continued service through each applicable vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 11, 2025 Filed Mar 12, 2025 23:31 UTC | Century Therapeutics, Inc. IPSC · Entity 5739 | GrantStock Option (right to buy) · Derivative | 19,500 | $0.00 Strike: $0.60 | $0.00 |
DisclosureSEC source: 0001062993-25-005294 · form4.xml · derivative · entry 2 Conn Morgan · CIK 0001974124 · Chief Finanical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,500 Underlying: Common Stock · 19,500 shares Expires 2035-03-11 F2 · derivative.exercise_date: The option vests 25% on March 11, 2026, with the remaining 75% vesting in 36 equal monthly installments, subject to the Reporting Person's continued service through each applicable vesting date. Read SEC document |
| March 11, 2025 Filed Mar 12, 2025 23:31 UTC | Century Therapeutics, Inc. IPSC · Entity 5739 | GrantCommon Stock | 19,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-005294 · form4.xml · nonDerivative · entry 1 Conn Morgan · CIK 0001974124 · Chief Finanical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,648 F1 · security: Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Issuer common stock. The RSUs vest 25% on March 11, 2026, with the remaining 75% vesting on a quarterly basis for the three years thereafter, in each case subject the Reporting Person's continued service through the applicable vesting date. The RSUs will be settled on each applicable vesting date in shares of the Issuer's common stock. Read SEC document |
| October 14, 2024 Filed Oct 16, 2024 20:58 UTC | Century Therapeutics, Inc. IPSC · Entity 5739 | GrantStock Option (right to buy) · Derivative | 360,890 | $0.00 Strike: $1.48 | $0.00 |
DisclosureSEC source: 0001062993-24-017718 · form4.xml · derivative · entry 2 Conn Morgan · CIK 0001974124 · Chief Finanical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 360,890 Underlying: Common Stock · 360,890 shares Expires 2034-10-14 F2 · derivative.exercise_date: The option vests 25% on October 14, 2025, with the remaining 75% vesting in 36 equal monthly installments, subject to the Reporting Person's continued service through each applicable vesting date. Read SEC document |
| October 14, 2024 Filed Oct 16, 2024 20:58 UTC | Century Therapeutics, Inc. IPSC · Entity 5739 | GrantCommon Stock | 60,148 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-017718 · form4.xml · nonDerivative · entry 1 Conn Morgan · CIK 0001974124 · Chief Finanical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,148 F1 · security: Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Century Therapeutics, Inc.'s (the "Company's") common stock. The RSUs vest 25% on October 14, 2025, with the remaining 75% vesting on a quarterly basis for the three years thereafter, in each case subject the Reporting Person's continued service through the applicable vesting date. The RSUs will be settled on each applicable vesting date in shares of the Company's common stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.